胸腺瘤非手术治疗的研究进展

doi:10.3760/cma.j.issn.1004-4221.2018.06.015

摘要
图/表
参考文献()
相关文章 (15)
点击分布统计
下载分布统计

全文: PDF (0 KB) HTML (1 KB)
输出: BibTeX | EndNote (RIS) 背景资料

摘要

对于不能手术的胸腺瘤患者常采用放疗、化疗、免疫治疗及靶向治疗等非手术治疗或综合治疗。对于局部晚期胸腺瘤,首选手术治疗,术后辅助放化疗;不能手术的患者可先行诱导治疗,再予以手术治疗和术后辅助放化疗。目前,胸腺瘤尚无统一的治疗标准,临床还处于研究探索阶段。本研究就胸腺瘤非手术治疗的预后进行综述,以期为临床治疗提供参考。

	服务

	把本文推荐给朋友
	加入我的书架
	加入引用管理器
	E-mail Alert
	RSS
	作者相关文章
	王晓丹
	冯勤付

关键词 ：胸腺肿瘤/放射疗法, 胸腺肿瘤/化学疗法, 研究进展

Abstract：

Thymoma of non-surgical treatment or combined modality therapy must be considered in advanced or unresectable cases, which includes radiotherapy, chemotherapy, targeted therapy and immunotherapy. The first choice of resectable advanced thymoma is surgery followed by adjuvant radiotherapy or chemotherapy. For unresectable advanced thymoma, inducted therapy followed by surgery and adjuvant therapy is a rational pattern. But the best treatment mode is still unclear. We review the effect and prognosis about non-surgical treatment of thymoma recent years, to offer advice about making the best decision in the treatment of thymoma.

Key words： Thymic neoplasms/radiotherapy Thymic neoplasms/chemotherapy Research progress

收稿日期: 2017-03-20

通讯作者: 冯勤付,Email:qinfufeng19@163.com

引用本文:

王晓丹,冯勤付. 胸腺瘤非手术治疗的研究进展[J]. 中华放射肿瘤学杂志, 2018, 27(6): 607-611.

Wang Xiaodan,Feng Qingfu. Thymic tumor:a systematic review of non-surgical treatment[J]. Chinese Journal of Radiation Oncology, 2018, 27(6): 607-611.

链接本文:

http://journal12.magtechjournal.com/Jweb_fszlx/CN/10.3760/cma.j.issn.1004-4221.2018.06.015 或 http://journal12.magtechjournal.com/Jweb_fszlx/CN/Y2018/V27/I6/607

[1] Engels EA.Epidemiology of thymoma and associated malignancies[J].J Thorac Oncol,2010,5(10 Suppl 4):S260-S265.DOI:10.1097/JTO.0b013e3181f1f62 d.
[2] Siesling S,van der Zwan J M,Izarzugaza I,et al. Rare thoracic cancers,including peritoneum mesothelioma[J].Eur J Cancer,2012,48(7):949-960.DOI:10.1016/j.ejca.2012.02.047.
[3] 方文涛,傅剑华,沈毅,等.胸腺肿瘤的诊疗:基于中国胸腺肿瘤协作组多中心回顾性研究的共识[J].中国肺癌杂志,2016,19(7):414-417.DOI:10.3779/j.issn.1009-3419.2016.07.02.
Fang WT,Fu JH,Shen Y,et al. Management of thymic tumors-consensus based on the chinese alliance for research in thymomas multi-institutional retrospective studies[J].Chin J Lung Cancer,2016,19(7):414-417.DOI:10.3779/j.issn.1009-3419.2016.07.02.
[4] Travis WD,Brambilla E,Muller-Hermelink HK,et al. Pathology and genetics of tumors of the lung[J].Pleura,Thymus Heart2004.DOI:10.1002/9781118010136.ch12.
[5] Patel S,Macdonald O K,Nagda S,et al. Evaluation of the role of radiation therapy in the management of malignant thymoma[J].Int J Radiat Oncol Biol Phys,2012,82(5):1797-1801.DOI:10.1016/j.ijrobp.2011.03.010.
[6] Margaritora S,Cesario A,Cusumano G,et al. Thirty-five-year follow-up analysis of clinical and pathologic outcomes of thymoma surgery[J].Ann Thorac Surg,2010,89(1):245-252,252.DOI:10.1016/j.athoracsur.2009.08.074.
[7] Ahmad U,Huang J.Induction therapy for thymoma[J].Thorac Surg Clin,2016,26(3):325-332.DOI:10.1016/j.thorsurg.2016.04.011.
[8] Gomez D,Komaki R,Yu J,et al. Radiation therapy definitions and reporting guidelines for thymic malignancies[J].J Thorac Oncol,2011,6(7 Suppl 3):S1743-S1748.DOI:10.1097/JTO.0b013e31821ea60c.
[9] Kim ES,Putnam JB,Komaki R,et al. Phase Ⅱ study of a multidisciplinary approach with induction chemotherapy,followed by surgical resection,radiation therapy,and consolidation chemotherapy for unresectable malignant thymomas:final report[J].Lung Cancer,2004,44(3):369-379.DOI:10.1016/j.lungcan.2003.12.010.
[10] Lucchi M,Melfi F,Dini P,et al. Neoadjuvant chemotherapy for stage Ⅲ and ⅣA thymomas:a single-institution experience with a long follow-up[J].J Thorac Oncol,2006,1(4):308-313.DOI:10.1016/S1556-0864(15)31586-0.
[11] Kunitoh H,Tamura T,Shibata T,et al. A phase Ⅱ trial of dose-dense chemotherapy,followed by surgical resection and/or thoracic radiotherapy,in locally advanced thymoma:report of a Japan Clinical Oncology Group trial (JCOG 9606)[J].Br J Cancer,2010,103(1):6-11.DOI:10.1038/sj.bjc.6605731.
[12] Park S,Ahn MJ,Ahn JS,et al. A prospective phase Ⅱ trial of induction chemotherapy with docetaxel/cisplatin for Masaoka stage Ⅲ/Ⅳ thymic epithelial tumors[J].J Thorac Oncol,2013,8(7):959-966.DOI:10.1097/JTO.0b013e318292c41e.
[13] Korst RJ,Bezjak A,Blackmon S,et al. Neoadjuvant chemoradiotherapy for locally advanced thymic tumors:a phase Ⅱ,multi-institutional clinical trial[J].J Thorac Cardiovasc Surg,2014,147(1):36-44,41-46.DOI:10.1016/j.jtcvs.2013.08.061.
[14] 谭黎杰,仇德惠,王群.术前化疗及手术治疗Ⅲ期、Ⅳ a期恶性胸腺瘤[J].中华肿瘤杂志,2000,22(4):327.DOI:10.3760/j.issn:0253-3766.2000.04.021.
Tan LJ,Qiu DH,Wang Q.Preoprative chemotherapy and opration for invasive Masaoka stage Ⅲ and Ⅳ a thymoma[J].Chin J Oncol,2000,22(4):327.DOI:10.3760/j.issn:0253-3766.2000.04.021.
[15] Wright CD,Choi NC,Wain JC,et al. Induction chemoradiotherapy followed by resection for locally advanced Masaoka stage Ⅲ and ⅣA thymic tumors[J].Ann Thorac Surg,2008,85(2):385-389.DOI:10.1016/j.athoracsur.2007.08.051.
[16] Mineo TC,Mineo D,Onorati I,et al. New predictors of response to neoadjuvant chemotherapy and survival for invasive thymoma:a retrospective analysis[J].Ann Surg Oncol,2010,17(11):3022-3029.DOI:10.1245/s10434-010-1134-9.
[17] Cardillo G,Lucchi M,Marulli G,et al. Induction therapy followed by surgical resection in Stage-Ⅲ thimic epithelial tumors:Long-term results from a multicentre analysis of 108 cases[J].Lung Cancer,2016,93(Mar):88-94.DOI:10.1016/j.lungcan.2016.01.008.
[18] 朱江,王祥,何金涛.诱导治疗后手术切除Ⅲ、Ⅳ a期侵袭性胸腺瘤的临床分析[J].中华内分泌外科杂志,2016,10(3):228-231.DOI:10.3760/cma.j.issn.1674-6090.2016.03.013.
Zhu J,Wang X,He JT.Surgical resection of stage Ⅲ and Ⅳ a invasive thymoma after inductive chemoradiotherapy[J].中华内分泌外科杂志,2016,10(3):228-231.DOI:10.3760/cma.j.issn.1674-6090.2016.03.013.
[19] 魏煜程,谷志涛,沈毅,等.ChART回顾性数据库局部进展期胸腺瘤的术前诱导治疗效果分析[J].中国肺癌杂志,2016,19(7):445-452.
Wei HC,Gu ZT,Shen Y,et al. Surgical resection of stage Ⅲ and Ⅳ a invasive thymoma after inductive chemoradiotherapy[J].Chin J Lung Cancer,2016,19(7):445-452.
[20] Hamaji M,Ali SO,Burt BM.A meta-analysis of induction therapy for advanced thymic epithelial tumors[J].Ann Thorac Surg,2015,99(5):1848-1856.DOI:10.1016/j.athoracsur.2014.12.048.
[21] Leuzzi G,Rocco G,Ruffini E,et al. Multimodality therapy for locally advanced thymomas:A propensity score-matched cohort study from the European Society of Thoracic Surgeons Database[J].J Thorac Cardiovasc Surg,2016,151(1):47-57.DOI:10.1016/j.jtcvs.2015.08.034.
[22] Girard N,Lal R,Wakelee H,et al. Chemotherapy definitions and policies for thymic malignancies[J].J Thorac Oncol,2011,6(7 Suppl 3):S1749-S1755.DOI:10.1097/JTO.0b013e31821ea5f7.
[23] Sur RK,Pacella JA,Donde B,et al. Role of radiotherapy in stage Ⅲ invasive thymomas[J].S Afr J Surg,1997,35(4):206-209.
[24] 马绍峰,伍炜,应克明,等.立体定向放射治疗胸腺瘤17例[J].蚌埠医学院学报,2007,32(1):95-96.DOI:10.3969/j.issn.1000-2200.2007.01.044.
Ma SF,He W,Ying KM,et al. Stereotactic radiotherapy for 17 cases of thymoma[J].J Bengbu Med College,2007,32(1):95-96.DOI:10.3969/j.issn.1000-2200.2007.01.044.
[25] Vogel J,Berman AT,Lin L,et al. Prospectivestudy of proton beam radiation therapy for adjuvant and definitive treatment of thymoma and thymic carcinoma:Early response and toxicity assessment[J].Radiother Oncol,2016,118(3):504-509.DOI:10.1016/j.radonc.2016.02.003.
[26] 王常禄,吕长兴,王家明,等.无法手术切除的30例胸腺瘤行放疗或放疗联合化疗的疗效分析[J].肿瘤,2009,29(4):370-373.DOI:10.3781/j.issn.1000-7431.2009.04.017.
Wang CL,Lyu CX,Wang JM,et al. An analysis on the efficiency of radiotherapy or combined chemoradiotherapy on 30 cases of unresectable thymus neoplasm[J].Oncology,2009,29(4):370-373.DOI:10.3781/j.issn.1000-7431.2009.04.017.
[27] 马业罡,贾鑑慧,李季,等.同期放化疗治疗Ⅳ a期胸腺瘤近期疗效观察[J].山东医药,2010,50(23):97-98.
Ma YG,Jia JH,Li J,et al. An analysis on the efficiency of radiotherapy or combined chemoradiotherapy on 30 cases of unresectable thymus neoplasm[J].Shandong Med Pharm,2010,50(23):97-98.
[28] Loehrer PS,Chen M,Kim K,et al. Cisplatin,doxorubicin,and cyclophosphamide plus thoracic radiation therapy for limited-stage unresectable thymoma:an intergroup trial[J].J Clin Oncol,1997,15(9):3093-3099.DOI:10.1200/JCO.1997.15.9.3093.
[29] Tamiya A,Matsumura A,Tsuji T,et al. A pilot study of cisplatin and etoposide with and without radiotherapy for advanced malignant thymoma[J].Anticancer Res,2014,34(4):2023-2027.
[30] Sakai M,Onuki T,Inagaki M,et al. Early-stage thymic carcinoma:is adjuvant therapy required?[J].J Thorac Dis,2013,5(2):161-164.DOI:10.3978/j.issn.2072-1439.2013.01.06.
[31] Wei ML,Kang D,Gu L,et al. Chemotherapy for thymic carcinoma and advanced thymoma in adults[J].Cochrane Database Syst Rev,2013(8):D8588.DOI:10.1002/14651858.CD008588.pub2.
[32] Fornasiero A,Daniele O,Ghiotto C,et al. Chemotherapy for invasive thymoma. A 13-year experience[J].Cancer,1991,68(1):30-33.
[33] Kim BK,Cho BC,Choi HJ,et al. A single institutional experience of surgically resected thymic epithelial tumors over 10 years:clinical outcomes and clinicopathologic features[J].Oncol Rep,2008,19(6):1525-1531.DOI:10.3892/or.19.6.1525.
[34] Loehrer PS,Jiroutek M,Aisner S,et al. Combined etoposide,ifosfamide,and cisplatin in the treatment of patients with advanced thymoma and thymic carcinoma:an intergroup trial[J].Cancer,2001,91(11):2010-2015.
[35] Lemma GL,Lee JW,Aisner SC,et al. Phase Ⅱ study of carboplatin and paclitaxel in advanced thymoma and thymic carcinoma[J].J Clin Oncol,2011,29(15):2060-2065.DOI:10.1200/JCO.2010.32.9607.
[36] Hirai F,Yamanaka T,Taguchi K,et al. A multicenter phase Ⅱ study of carboplatin and paclitaxel for advanced thymic carcinoma:WJOG4207L[J].Ann Oncol,2015,26(2):363-368.DOI:10.1093/annonc/mdu541.
[37] 姬巍,冯勤富,周宗玫,等.73例胸腺癌的治疗与预后分析[J].中华放射肿瘤学杂志,2006,15(2):97-100.DOI:10.3760/j.issn:1004-4221.2006.02.007.
Ji W,Feng QF,Zhou ZM,et al. Analysis of treatment and prognosis of 73 thymic carcinoma patients[J].Chin J Radiat Oncol,2006,15(2):97-100.DOI:10.3760/j.issn:1004-4221.2006.02.007.
[38] Chen YD,Feng QF,Lu HZ,et al. Role of adjuvant radiotherapy for stage Ⅱ thymoma after complete tumor resection[J].Int J Radiat Oncol Biol Phys,2010,78(5):1400-1406.DOI:10.1016/j.ijrobp.2009.09.066.
[39] Fan C,Feng Q,Chen Y,et al. Postoperativeradiotherapy for completely resected Masaoka stage Ⅲ thymoma:a retrospectiveive study of 65 cases from a single institution[J].Radiat Oncol,2013,8:199.DOI:10.1186/1748-717X-8-199.
[40] Forquer JA,Rong N,Fakiris AJ,et al. Postoperative radiotherapy after surgical resection of thymoma:differing roles in localized and regional disease[J].Int J Radiat Oncol Biol Phys,2010,76(2):440-445.DOI:10.1016/j.ijrobp.2009.02.016.
[41] Berman A T,Litzky L,Livolsi V,et al. Adjuvant radiotherapy for completely resected stage 2 thymoma[J].Cancer,2011,117(15):3502-3508.DOI:10.1002/cncr.25851.
[42] Weksler B,Shende M,Nason KS,et al. The role of adjuvant radiation therapy for resected stage Ⅲ thymoma:a population-based study[J].Ann Thorac Surg,2012,93(6):1822-1828,1828-1829.DOI:10.1016/j.athoracsur.2012.03.004.
[43] Lim YJ,Kim HJ,Wu HG.Role of Postoperative Radiotherapy in nonlocalized thymoma:propensity-matched analysis of surveillance,epidemiology,and end results database[J].J Thorac Oncol,2015,10(9):1357-1363.DOI:10.1097/JTO.0000000000000619.
[44] Rimner A,Yao X,Huang J,et al. Postoperative Radiation therapy is associated with longer overall survⅳal in completely resected stage ⅱ and ⅲ thymoma-an analysis of the international thymic malignancies interest group retrospective database[J].J Thorac Oncol,2016,11(10):1785-1792.DOI:10.1097/JTO.0000000000000099.
[45] Boothe D,Orton A,Thorpe C,et al. Postoperative radiotherapy in locally invasive malignancies of the thymus:patterns of care and survival[J].J Thorac Oncol,2016,11(12):2218-2226.DOI:10.1016/j.jtho.2016.07.032.
[46] Yan J,Liu Q,Moseley JN,et al. Adjuvant Radiotherapy for stages ⅱ and ⅲ resected thymoma:a single-institutional experience[J].Am J Clin Oncol,2016,39(3):223-227.DOI::10.1097/COC.0000000000000044.
[47] 张红星,汪楣,谷铣之,等.Ⅰ期胸腺瘤的前瞻性临床治疗研究[J].中华放射肿瘤学杂志,1998(04):16-19.DOI:10.3760/j.issn:1004-4221.1998.04.005.
Zhang HX,Wang M,Gu XZ,et al. Postoperative radiotherapy for stage Ⅰ thymoma:a prospective randomized trial on 29 cases[J][J].Chin J Radiat Oncol,1998(04):16-19.DOI:10.3760/j.issn:1004-4221.1998.04.005.
[48] Ma J,Sun X,Huang L,et al. Postoperative radiotherapy and tumor recurrence after complete resection of stage Ⅱ/Ⅲ thymic tumor:a meta-analysis of cohort studies[J].Onco Targets Ther,2016,9:4517-4526.DOI:10.2147/OTT.S104435.
[49] Hamaji M,Shah RM,Ali SO,et al. A Meta-analysis of postoperative radiotherapy for thymic carcinoma[J].Ann Thorac Surg,2017,103(5):1668-1675.DOI:10.1016/j.athoracsur.2016.12.042.
[50] 范诚诚,冯勤付,毛友生,等.111例Ⅲ期胸腺瘤治疗结果分析[J].中华放射肿瘤学杂志,2012,21(6):513-517.DOI:10.3760/cma.j.issn.1004-4221.2012.06.009.
Fan CC,Feng QF,Mao YS,et al. Analysis of treatment outcome for stage Ⅲ thymoma[J].Chin J Radiat Oncol,2012,21(6):513-517.DOI:10.3760/cma.j.issn.1004-4221.2012.06.009.
[51] Regnard JF,Magdeleinat P,Dromer C,et al. Prognostic factors and long-term results after thymoma resection:a series of 307 patients[J].J Thorac Cardiovasc Surg,1996,112(2):376-384.DOI:10.1016/S0022-5223(96)70265-9.
[52] Nakagawa K,Asamura H,Matsuno Y,et al. Thymoma:a clinicopathologic study based on the new World Health Organization classification[J].J Thorac Cardiovasc Surg,2003,126(4):1134-1140.DOI:10.1016/S0022.
[53] Chen G,Marx A,Chen WH,et al. New WHO histologic classification predicts prognosis of thymic epithelial tumors:a clinicopathologic study of 200 thymoma cases from China[J].Cancer,2002,95(2):420-429.DOI:10.1002/cncr.10665.
[54] Xu C,Feng QF,Fan CC,et al. Patterns and predictors of recurrence after radical resection of thymoma[J].Radiother Oncol,2015,115(1):30-34.DOI:10.1016/j.radonc.2015.03.001.
[55] Kim HS,Lee JY,Lim SH,et al. A Prospective phase Ⅱ study of cisplatin and cremophor el-free paclitaxel (genexol-pm) in patients with unresectable thymic epithelial tumors[J].J Thorac Oncol,2015,10(12):1800-1806.DOI:10.1097/JTO.0000000000000692.
[56] Okuda K,Yano M,Yoshino I,et al. Thymoma patients with pleural dissemination:nationwide retrospective study of 136 cases in Japan[J].Ann Thorac Surg,2014,97(5):1743-1748.DOI:10.1016/j.athoracsur.2014.01.042.
[57] Rimner A,Gomez DR,Wu AJ,et al. Failure patterns relative to radiation treatment fields for stage Ⅱ-Ⅳ thymoma[J].J Thorac Oncol,2014,9(3):403-409.DOI:10.1016/j.jtho.2016.06.011.
[58] Palmieri G,Marino M,Buonerba C,et al. Imatinib mesylate in thymic epithelial malignancies[J].Cancer Chemother Pharmacol,2012,69(2):309-315.DOI:10.1007/s00280-011-1690-0.
[59] Rajan A,Carter CA,Berman A,et al. Cixutumumab for patients with recurrent or refractory advanced thymic epithelial tumours:a multicentre,open-label,phase 2 trial[J].Lancet Oncol,2014,15(2):191-200.DOI:10.1016/S1470-2045(13)70596-5.
[60] Thomas A,Rajan A,Berman A,et al. Sunitinib in patients with chemotherapy-refractory thymoma and thymic carcinoma:an open-label phase 2 trial[J].Lancet Oncol,2015,16(2):177-186.DOI:10.1016/S1470-2045(14)71181-7.
[61] Gubens MA,Burns M,Perkins SM,et al. A phase Ⅱ study of saracatinib (AZD0530),a Src inhibitor,administered orally daily to patients with advanced thymic malignancies[J].Lung Cancer,2015,89(1):57-60.DOI:10.1016/j.lungcan.2015.04.008.
[62] Gordon MS,Battiato LA,Gonin R,et al. A phase Ⅱ trial of subcutaneously administered recombinant human interleukin-2 in patients with relapsed/refractory thymoma[J].J Immunother Emphasis Tumor Immunol,1995,18(3):179-184.
[63] Katsuya Y,Horinouchi H,Asao T,et al. Expression of programmed death 1(PD-1) and its ligand (PD-L1) in thymic epithelial tumors:Impact on treatment efficacy and alteration in expression after chemotherapy[J].Lung Cancer,2016,99:4-10.DOI:10.1016/j.lungcan.2016.05.007.
[64] Katsuya Y,Fujita Y,Horinouchi H,et al. Immunohistochemical status of PD-L1 in thymoma and thymic carcinoma[J].Lung Cancer,2015,88(2):154-159.DOI:10.1016/j.lungcan.2015.03.003.
[65] Kirzinger L,Boy S,Marienhagen J,et al. Octreotide LAR and prednisone as neoadjuvant treatment in patients with primary or locally recurrent unresectable thymic tumors:a phase Ⅱ study[J].PLoS One,2016,11(12):e168215.DOI:10.1371/journal.pone.0168215.